×
Champions Oncology Income Taxes 2010-2024 | CSBR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Champions Oncology income taxes from 2010 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.
View More
Champions Oncology Income Taxes 2010-2024 | CSBR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Champions Oncology income taxes from 2010 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$80.4B
Zoetis (ZTS)
$70.5B
Takeda Pharmaceutical (TAK)
$44.1B
Daiichi Sankyo, - (DSNKY)
$43.3B
Sandoz Group AG (SDZNY)
$20.6B
Merck (MKKGY)
$18.5B
Astellas Pharma (ALPMY)
$17.5B
Summit Therapeutics (SMMT)
$17B
United Therapeutics (UTHR)
$16.4B
Shionogi (SGIOY)
$12.3B
Neurocrine Biosciences (NBIX)
$11.6B
Orion OYJ (ORINY)
$7.7B
Madrigal Pharmaceuticals (MDGL)
$7.7B
Corcept Therapeutics (CORT)
$6.8B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Stevanato Group S.p.A (STVN)
$6.2B
Ionis Pharmaceuticals (IONS)
$5.2B
Grifols, S.A (GRFS)
$5.2B
Ono Pharmaceutical (OPHLF)
$4.7B
Recursion Pharmaceuticals (RXRX)
$4B
Crinetics Pharmaceuticals (CRNX)
$3.4B
Catalyst Pharmaceuticals (CPRX)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.4B
Centessa Pharmaceuticals (CNTA)
$2.2B
Hypermarcas (HYPMY)
$2.2B
Soleno Therapeutics (SLNO)
$2B
BioCryst Pharmaceuticals (BCRX)
$1.9B
NewAmsterdam Pharma (NAMS)
$1.8B
Evotec AG (EVO)
$1.6B
Dyne Therapeutics (DYN)
$1.4B